Cargando…
A new extended release formulation (OROS(®)) of hydromorphone in the management of pain
Opioid analgesics are essential in the treatment of moderate to severe cancer-related pain. Opioids are also recognized as important in the management of other severe, persistent refractory painful conditions, such as sickle cell disease and arthritis. In the clinical practice of pain management, st...
Autor principal: | Weinstein, Sharon M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2697506/ https://www.ncbi.nlm.nih.gov/pubmed/19436600 |
Ejemplares similares
-
Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain
por: Vandenbossche, Joris, et al.
Publicado: (2012) -
Pharmacokinetic profile of a 24-hour controlled-release OROS(® )formulation of hydromorphone in the presence and absence of food
por: Sathyan, Gayatri, et al.
Publicado: (2007) -
A randomized, double-blind comparison of OROS(® )hydromorphone and controlled-release morphine for the control of chronic cancer pain
por: Hanna, Magdi, et al.
Publicado: (2008) -
Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain: a dose-conversion and titration study
por: Wallace, M, et al.
Publicado: (2007) -
Effectiveness and gastrointestinal tolerability during conversion and titration with once-daily OROS® hydromorphone extended release in opioid-tolerant patients with chronic low back pain
por: Hale, Martin E, et al.
Publicado: (2013)